MediGene appoints Arnd Christ as Chief Financial Officeras Successor to Dr. Thomas Klaue
(Thomson Reuters ONE) -
MediGene AG / MediGene appoints Arnd Christ as Chief Financial Officeras Successor to Dr. Thomas Klaue processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, March 26, 2010.The biotech company MediGene AG (Frankfurt,
Prime Standard, TecDAX) today announced that Chief Financial Officer Dr. Thomas
Klaue will leave the company for different opinions in strategic directions of
the company by mutual consent with the Supervisory Board in May 2010. Dr. Klaue
will resign from office after the Annual Shareholders' Meeting on May 11, 2010,
and his employment contract will cease in June 2010. Arnd Christ has been chosen
to succeed Dr. Klaue as Chief Financial Officer. Mr. Christ has many years'
management experience in the biotech and pharmaceuticals industry, and has held
his current position as Chief Financial Officer at the Swiss biotechnology
company NovImmune since 2007.
Prof. Dr. Ernst-Ludwig Winnacker, Chairman of the Supervisory Board of MediGene
AG, commented: "On behalf of the Supervisory and Executive Boards, I would like
to express our heartfelt thanks to Dr. Thomas Klaue for his commitment to, and
success in building, MediGene over the past three years. He has shaped our
business and financial profile by significantly reducing the Cost, improving the
EBITDA and stabilized Liquidity, not least due to the SEDA financial instrument
which was successfully introduced by Dr. Klaue in Germany for the first time. We
are delighted that in his successor Arnd Christ, MediGene has been able to
attract such a highly qualified CFO with deep and long-term experience in the
biotechnology industry. We are happy to welcome Arnd Christ to MediGene, and
look forward to using his expertise and dynamism in taking our business
forward."
Arnd Christ has 15 years of international experience in business finance and
management as well as mergers and acquisitions. In his capacity as Chief
Financial Officer at the biotech company NovImmune SA, Geneva, Switzerland, he
was responsible for the successful closing of one of the largest private
financing rounds (CHF 62.5 million) in the European biotech industry. Prior to
joining NovImmune, Mr. Christ held the position as Chief Financial Officer of
Probiodrug AG, Halle, for 5 years, where he was responsible for several fund
raising rounds as well as for the successful closing of a major asset sale to
OSI Pharmaceuticals Inc. Before joining Probiodrug AG, Arnd Christ was finance
manager at several subsidiaries of the Hoechst Group in Germany and UK. Arnd
Christ studied at the Julius-Maximilians-Universität in Würzburg and holds a
degree in business administration.
This press release contains forward-looking statements representing the opinion
of MediGene as of the date of this release. The actual results achieved by
MediGene may differ significantly from the forward-looking statements made
herein. MediGene is not bound to update any of these forward-looking statements.
MediGene(®) is a registered trademark of MediGene AG. This trademark may be
owned or licensed in select locations only.
- ends -
MediGene AG is a publicly listed (Frankfurt, Prime Standard: MDG, TecDax)
biotechnology company located in Martinsried/Munich, Germany, with subsidiaries
in Oxford, UK and San Diego, USA. MediGene is the first German biotech company
to have drugs on the market which are distributed by partner companies. It has
several drug candidates in clinical development and possesses innovative
platform technologies. MediGene focuses on clinical research and development of
novel drugs with focus on oncology.
Contact MediGene AG
Email: investor(at)medigene.com
Fax: ++49 - 89 - 85 65 - 2920
Julia Hofmann / Dr. Nadja Wolf, Public Relations, Tel.: ++49 - 89 - 85 65 - 3324
Dr. Georg Dönges, Investor Relations, Tel.: ++49 - 89 - 85 65 - 2946
[HUG#1398068]
--- End of Message ---
MediGene AG
Lochhamer Strasse 11 Martinsried / München Germany
WKN: 502090;ISIN: DE0005020903 ;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 26.03.2010 - 02:30 Uhr
Sprache: Deutsch
News-ID 1011977
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Martinsried / München
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 106 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MediGene appoints Arnd Christ as Chief Financial Officeras Successor to Dr. Thomas Klaue
"
steht unter der journalistisch-redaktionellen Verantwortung von
MediGene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
